Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540826 | 0.85 | VCAM1 (0.42) | ALDH1A1LMNATSHRKMT2AMEP1B | |
| SCHEMBL3918873 | 0.83 | ALDH1A1 (0.39) | ALDH1A1LMNAMETAP2WDR5KMT2A | |
| SCHEMBL2538476 | 0.82 | LMNA (0.54) | ALDH1A1LMNATSHRWDR5MAPK1 | |
| SCHEMBL2536209 | 0.77 | CYP3A4 (0.39) | ALDH1A1LMNATSHRCA12CA9 | |
| SCHEMBL2538158 | 0.77 | CA12 (0.47) | ALDH1A1TSHRCA12CA9METAP2 | |
| SCHEMBL11174978 | 0.75 | AKR1C3 (0.59) | LMNACA9CA2KMT2A | |
| SCHEMBL2540297 | 0.74 | CA12 (0.47) | ALDH1A1LMNATSHRCA12CA9 | |
| SCHEMBL13614102 | 0.74 | MEN1 (0.57) | ALDH1A1LMNATSHRKMT2AHSD17B10 | |
| SCHEMBL3530381 | 0.74 | CA2 (0.46) | ALDH1A1CA12CA9CA2CA4 | |
| SCHEMBL13451131 | 0.74 | CYP1A2 (0.59) | ALDH1A1LMNAWDR5MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | ALDH1A1 2969/4885LMNA 4383/4885TSHR 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.